Evidence map›Paper›PMID 36013563›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Statin Prescription Patterns and Associations with Subclinical Inflammation.

Preetham Kadappu, Jitendra Jonnagaddala, Siaw-Teng Liaw, Blake J Cochran, Kerry-Anne Rye, Kwok Leung Ong

Registry-linked trialFull text read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06871358 (The Effect of Pre- and Post-Administration of 80 mg Atorvastatin on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in STEMI Patients Undergoing Primary PCI), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06871358 nacompletednot on this mapstarted 2024, after this paper: background citation

The Effect of Pre- and Post-Administration of 80 mg Atorvastatin on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in STEMI Patients Undergoing Primary PCI

TypeinterventionalSponsorUniversitas Sebelas MaretRan2024 to 2024Enrolled40ConditionsSTEMI (STE-ACS), Primary PCI for STEMIArmsAtorvastatin 80mg, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Preetham KadappuSchool of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-9692-0148
Jitendra JonnagaddalaSchool of Population Health, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-9912-2344
Siaw-Teng LiawSchool of Population Health, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-5989-3614
Blake J CochranSchool of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-9615-7939
Kerry-Anne RyeSchool of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-9751-917X
Kwok Leung OngSchool of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.

Funding

National Health and Medical Research Council 1122854National Health and Medical Research Council 1148468National Health and Medical Research Council 2004064
6 · The paper itself

Abstract

Background and Objectives: Statins have been extensively utilised in atherosclerotic cardiovascular disease (ASCVD) prevention and can inhibit inflammation. However, the association between statin therapy, subclinical inflammation and associated health outcomes is poorly understood in the primary care setting. Materials and Methods: Primary care electronic health record (EHR) data from the electronic Practice-Based Research Network (ePBRN) from 2012−2019 was used to assess statin usage and adherence in South-Western Sydney (SWS), Australia. Independent determinants of elevated C-reactive protein (CRP) were determined. The relationship between baseline CRP levels and hospitalisation rates at 12 months was investigated. Results: The prevalence of lipid-lowering medications was 14.0% in all adults and 44.6% in the elderly (≥65 years). The prevalence increased from 2012 to 2019 despite a drop in statin use between 2013−2015. A total of 55% of individuals had good adherence (>80%). Hydrophilic statin use and higher intensity statin therapy were associated with elevated CRP levels. However, elevated CRP levels were not associated with all-cause or ASCVD hospitalisations after adjusting for confounders. Conclusions: The prevalence and adherence patterns associated with lipid-lowering medications highlighted the elevated ASCVD-related burden in the SWS population, especially when compared with the Australian general population. Patients in SWS may benefit from enhanced screening protocols, targeted health literacy and promotion campaigns, and timely incorporation of evidence into ASCVD clinical guidelines. This study, which used EHR data, did not support the use of CRP as an independent marker of future short-term hospitalisations.

Indexed as

AtherosclerosisCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsAdultAgedAustraliaHumansInflammationLipidsPrescriptionsHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsatherosclerosiscardiovascular diseaseshospitalisationsinflammationprescribingstatins

Identifiers

PMID36013563
PMCPMC9414401

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.